Back to search results

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer · Triple Negative Breast Cancer · Residual Cancer · Circulating Tumor DNA

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Jo Chien, MD) · jchien@medicine.ucsf.edu
    Contact: Principal Investigator (Jo Chien, MD)

  • University of Chicago Medical Center, Chicago, Illinois, United States

  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox, Illinois, United States

  • University of Chicago Medical Center for Advanced Care Orland Park, Orland Park, Illinois, United States

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Elizabeth A Mittendorf, MD, PhD) · emittendorf@bwh.harvard.edu · 617-582-9980
    Contact: Principal Investigator (Elizabeth A Mittendorf, MD, PHD)

  • University of Pennsylvania-Abramson Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Angela DeMichele, MD) · angela.demichele@uphs.upenn.edu · 215-349-5319
    Contact: Principal Investigator (Angela DeMichele, MD)

  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Vandana Abramson, MD) · vandana.abramson@vanderbilt.edu
    Contact: Principal Investigator (Vandana Abramson, MD)
Study leads

  • Elizabeth A Mittendorf, MD, PhD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)